Q32 Bio Inc. Common Stock

Day range

$8.39 – $8.83

Open

$8.60

Prev close

$8.65

Volume

319.4K

Market cap

$257.51M

Shares out

29.77M

P/E

7.62

P/S

4.79

P/B

2.43

P/FCF

—

ROE

31.9%

ROA

29.2%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsSep 30, 2026

  Bempikibart was observed to have a generally well-tolerated safety profile in SIGNAL-AA Part B, consistent with prior studies. No new safety signals were observed. There were no serious adverse events or Grade 3 or higher adverse events related to treatment.

• Executive officer appointmentSep 14, 2026

  Also on September 14, 2026, the Company announced the appointment of Ellie Hershberger, Pharm. D. as its Chief Development Officer.

• Underwriting agreementJul 15, 2026

  On July 14, 2026, Q32 Bio Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC, Jefferies LLC, Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc., as representatives (the "Representatives") of the several underwriters named therein (the "Underwriters")...Pursuant to the Underwriting Agreement, the Company granted the underwriters a 30-day option to purchase up to an additional 1,643,835 shares of its Common Stock (the "Optional Shares," and together with the Firm Shares, the "Shares") at the public offering price, less underwriting discounts and commissions.

• Clinical trial resultsJul 13, 2026

  On July 13, 2026, Q32 Bio Inc. (the "Company") used a presentation in connection with its announcement of the topline results from the Part B of the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart (ADX-914) in patients with alopecia areata ("AA")

• Debt retirementJul 13, 2026

  On June 24, 2026, the Company paid off the remaining balance in the amount of approximately $6.8 million under the Loan and Security Agreement (the 'Loan Agreement') between the Company and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company ('SVB'), pursuant to a Pay-Off Letter between the Company and SVB dated June 24, 2026. Accordingly, the Loan Agreement has been terminated.

Days to cover

4.3

Short interest

4.67M

Avg volume

1.08M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Why Is Q32 Bio Stock Gaining Friday?
  positiveBenzinga· May 29, 2026
• Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
  positiveBenzinga· Dec 1, 2025
• Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
  Benzinga· Apr 15, 2024